Replies to post #233320 on Avid Bioservices Inc (CDMO)

[EndoTarget]

“After working on 17 drug approvals, it is data like this
that continues to energize me. These robust data will be
important in discussions with the FDA regarding
advancing bavituximab’s clinical development in secondline
non-small cell lung cancer,” said Robert Garnick,
PhD, head of regulatory affairs at Peregrine. “We look
forward to working closely with the FDA to identify the
most efficient path toward commercialization for this
promising candidate in this indication where new
therapies are desperately needed.”